Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on December 17, 2020, covering events occurring on December 15 and 16, 2020. The filing primarily addresses executive leadership changes within the finance department.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel transitions and associated compensation arrangements.
Material Changes
- Departure of CFO: John T. Maxwell announced his intent to resign as Chief Financial Officer, with an anticipated departure date at year-end 2020.
- Appointment of Interim CFO: The Board appointed Ernie Toth as Interim Chief Financial Officer, effective upon Mr. Maxwell's departure.
- Severance Package: Mr. Maxwell's separation agreement includes a severance payment equal to his annual base salary plus target annual bonus (payable in 12 monthly installments), a 2020 target bonus, up to 12 months of health/life insurance coverage, and immediate vesting of all unvested stock options (exercisable for one year).
- Interim Compensation: Mr. Toth will serve as a consultant via Danforth Advisors, LLC, at a rate of $325 per hour, plus stock options for 2,500 shares and reimbursement of commuting and business expenses.
Guidance, Outlook, and Risks
Management confirmed via press release that there is no change to the Company's full-year 2020 financial outlook. The filing notes that Mr. Toth has no family relationships with current directors or officers and no undisclosed transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the exact date of Mr. Maxwell's final departure to confirm the timeline for the interim CFO transition.
- Review the specific terms of the 2018 Equity Incentive Plan regarding the 2,500 stock options granted to Mr. Toth.
- Monitor subsequent filings for the appointment of a permanent Chief Financial Officer.
- Confirm the impact of the immediate vesting of Mr. Maxwell's options on the company's share count and dilution.